Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eyepoint Inc (EYPT)

Eyepoint Inc (EYPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,183,900
  • Shares Outstanding, K 83,432
  • Annual Sales, $ 31,370 K
  • Annual Income, $ -231,960 K
  • EBIT $ -243 M
  • EBITDA $ -246 M
  • 60-Month Beta 1.89
  • Price/Sales 37.85
  • Price/Cash Flow N/A
  • Price/Book 3.85

Options Overview Details

View History
  • Implied Volatility 89.12% (+6.17%)
  • Historical Volatility 64.64%
  • IV Percentile 51%
  • IV Rank 21.53%
  • IV High 219.91% on 02/13/26
  • IV Low 53.23% on 07/30/25
  • Expected Move (DTE 4) 1.23 (8.72%)
  • Put/Call Vol Ratio 0.14
  • Today's Volume 8
  • Volume Avg (30-Day) 675
  • Put/Call OI Ratio 0.85
  • Today's Open Interest 35,281
  • Open Int (30-Day) 28,354
  • Expected Range 12.91 to 15.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.79
  • Number of Estimates 3
  • High Estimate $-0.76
  • Low Estimate $-0.81
  • Prior Year $-0.65
  • Growth Rate Est. (year over year) -21.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.82 +20.18%
on 03/30/26
14.53 -2.24%
on 04/13/26
+1.01 (+7.61%)
since 03/13/26
3-Month
11.82 +20.18%
on 03/30/26
18.87 -24.72%
on 03/02/26
-1.73 (-10.83%)
since 01/13/26
52-Week
5.14 +176.36%
on 04/14/25
19.11 -25.67%
on 12/08/25
+8.82 (+164.03%)
since 04/11/25

Most Recent Stories

More News
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass, March 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious...

EYPT : 14.37 (+1.27%)
EyePoint: Q4 Earnings Snapshot

EyePoint: Q4 Earnings Snapshot

EYPT : 14.37 (+1.27%)
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments

        – Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 – – Patients dosed in both COMO and CAPRI Phase 3 clinical trials for DURAVYU...

EYPT : 14.37 (+1.27%)
EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema

– Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets – – Topline data for DURAVYU in DME anticipated in 2H 2027 – WATERTOWN,...

EYPT : 14.37 (+1.27%)
EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026

WATERTOWN, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with...

EYPT : 14.37 (+1.27%)
EyePoint Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with...

EYPT : 14.37 (+1.27%)
EyePoint Appoints Michael Campbell as Chief Commercial Officer

– Seasoned commercial executive with over 30 years of leadership in retinal disease across biotech and large pharma – – Brings established track record of successful product launches and oversight...

EYPT : 14.37 (+1.27%)
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious...

EYPT : 14.37 (+1.27%)
EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

WATERTOWN, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with...

EYPT : 14.37 (+1.27%)
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious...

EYPT : 14.37 (+1.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

EYEPOINT INC is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. EYEPOINT INC, formerly known as EyePoint Pharmaceuticals Inc., is based in WATERTOWN, Mass.

See More

Key Turning Points

3rd Resistance Point 14.86
2nd Resistance Point 14.61
1st Resistance Point 14.40
Last Price 14.37
1st Support Level 13.94
2nd Support Level 13.69
3rd Support Level 13.48

See More

52-Week High 19.11
Last Price 14.37
Fibonacci 61.8% 13.77
Fibonacci 50% 12.13
Fibonacci 38.2% 10.48
52-Week Low 5.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.